|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vale C; Advanced Bladder Cancer
Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive
bladder cancer: A systematic review and meta-analysis. Lancet.
361:1927–1934. 2003. View Article : Google Scholar
|
|
4
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multi-center, phase III study. J Clin Oncol. 18:3068–3077. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meeks JJ, Bellmunt J, Bochner BH, Clarke
NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T,
et al: A systematic review of neoadjuvant and adjuvant chemotherapy
for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carthew RW and Sontheimer EJ: Origins and
Mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
8
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
13
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Block AL, Bauer KD, Williams TJ and
Seidenfeld J: Experimental parameters and a biological standard for
acridine orange detection of drug-induced alterations in chromatin
condensation. Cytometry. 8:163–169. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar A, Sahu SK, Mohanty S, Chakrabarti
S, Maji S, Reddy RR, Jha AK, Goswami C, Kundu CN, Rajasubramaniam
S, et al: Kaposi sarcoma herpes virus latency associated nuclear
antigen protein release the G2/M cell cycle blocks by modulating
ATM/ATR mediated checkpoint pathway. PLoS One. 9:e1002282014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B and Dewey CN: RSEM: Accurate
transcript quantification from RNA-Seq data with or without a
reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiao Y, Su C and Deng T: miR-223 decreases
cell proliferation and enhances cell apoptosis in acute myeloid
leukemia via targeting FBXW7. Oncol Lett. 12:3531–3536. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar
|
|
21
|
Ishihara T, Seki N, Inoguchi S, Yoshino H,
Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M,
et al: Expression of the tumor suppressive miRNA-23b/27b cluster is
a good prognostic marker in clear cell renal cell carcinoma. J
Urol. 192:1822–1830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada Y, Hidaka H, Seki N, Yoshino H,
Yamasaki T, Itesako T, Nakagawa M and Enokida H: Tumor-suppressive
microRNA-135a inhibits cancer cell proliferation by targeting the
c-MYC oncogene in renal cell carcinoma. Cancer Sci. 104:304–312.
2013. View Article : Google Scholar
|
|
23
|
Yamasaki T, Seki N, Yamada Y, Yoshino H,
Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M and
Enokida H: Tumor suppressive microRNA 138 contributes to cell
migration and invasion through its targeting of vimentin in renal
cell carcinoma. Int J Oncol. 41:805–817. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshino H, Enokida H, Itesako T, Kojima S,
Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M and Seki N:
Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in
renal cell carcinoma. Cancer Sci. 104:1567–1574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshino H, Enokida H, Itesako T, Tatarano
S, Kinoshita T, Fuse M, Kojima S, Nakagawa M and Seki N:
Epithelial-mesenchymal transition-related microRNA-200s regulate
molecular targets and pathways in renal cell carcinoma. J Hum
Genet. 58:508–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa
M, et al: MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J Urol. 190:1059–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Yamada Y, Tatarano S, Hidaka H, Yonezawa T, Nakagawa M and Enokida
H: Tumor-suppressive microRNA-1291 directly regulates glucose
transporter 1 in renal cell carcinoma. Cancer Sci. 104:1411–1419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhi Y, Pan J, Shen W, He P, Zheng J, Zhou
X, Lu G, Chen Z and Zhou Z: Ginkgolide B inhibits human bladder
cancer cell migration and invasion through microRNA-223-3p. Cell
Physiol Biochem. 39:1787–1794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Cao R, Yu X, Xiao Z and Chen Z:
MicroRNA-223-3p inhibits human bladder cancer cell migration and
invasion. Tumour Biol. 39:10104283176916782017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T,
Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al:
The sensitivity of gastric cancer to trastuzumab is regulated by
the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015.
View Article : Google Scholar
|
|
33
|
Li ZW, Yang YM, Du LT, Dong Z, Wang LL,
Zhang X, Zhou XJ, Zheng GX, Qu AL and Wang CX: Overexpression of
miR-223 correlates with tumor metastasis and poor prognosis in
patients with colorectal cancer. Med Oncol. 31:2562014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Melo Maia B, Rodrigues IS, Akagi EM,
Soares do Amaral N, Ling H, Monroig P, Soares FA, Calin GA and
Rocha RM: MiR-223-5p works as an oncomiR in vulvar carcinoma by
TP63 suppression. Oncotarget. 7:49217–49231. 2016.PubMed/NCBI
|
|
35
|
Sun X, Li Y, Zheng M, Zuo W and Zheng W:
MicroRNA-223 increases the sensitivity of triple-negative breast
cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1.
PLoS One. 11:e01627542016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang Y, Wang Y, Chen Q, Qiu N, Zhao Y and
You X: MiR-223 inhibited cell metastasis of human cervical cancer
by modulating epithelial-mesenchymal transition. Int J Clin Exp
Pathol. 8:11224–11229. 2015.PubMed/NCBI
|
|
37
|
Kurozumi A, Goto Y, Matsushita R, Fukumoto
I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa
T, et al: Tumor-suppressive microRNA-223 inhibits cancer cell
migration and invasion by targeting ITGA3/ITGB1 signaling in
prostate cancer. Cancer Sci. 107:84–94. 2016. View Article : Google Scholar
|
|
38
|
Shinmura K, Kato H, Kawanishi Y, Igarashi
H, Inoue Y, Yoshimura K, Nakamura S, Fujita H, Funai K, Tanahashi
M, et al: WDR62 overexpression is associated with a poor prognosis
in patients with lung adenocarcinoma. Mol Carcinog. 56:1984–1991.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wasserman T, Katsenelson K, Daniliuc S,
Hasin T, Choder M and Aronheim A: A novel c-Jun N-terminal kinase
(JNK)-binding protein WDR62 is recruited to stress granules and
mediates a nonclassical JNK activation. Mol Biol Cell. 21:117–130.
2010. View Article : Google Scholar :
|
|
40
|
Cohen-Katsenelson K, Wasserman T, Khateb
S, Whitmarsh AJ and Aronheim A: Docking interactions of the JNK
scaffold protein WDR62. Biochem J. 439:381–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kuan CY, Yang DD, Samanta Roy DR, Davis
RJ, Rakic P and Flavell RA: The Jnk1 and Jnk2 protein kinases are
required for regional specific apoptosis during early brain
development. Neuron. 22:667–676. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nicholas AK, Khurshid M, Désir J, Carvalho
OP, Cox JJ, Thornton G, Kausar R, Ansar M, Ahmad W, Verloes A, et
al: WDR62 is associated with the spindle pole and is mutated in
human microcephaly. Nat Genet. 42:1010–1014. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu TW, Mochida GH, Tischfield DJ, Sgaier
SK, Flores-Sarnat L, Sergi CM, Topçu M, McDonald MT, Barry BJ,
Felie JM, et al: Mutations in WDR62, encoding a
centrosome-associated protein, cause microcephaly with simplified
gyri and abnormal cortical architecture. Nat Genet. 42:1015–1020.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu D, Zhang F, Wang Y, Sun Y and Xu Z:
Microcephaly-associated protein WDR62 regulates neurogenesis
through JNK1 in the developing neocortex. Cell Rep. 6:104–116.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pervaiz N and Abbasi AA: Molecular
evolution of WDR62, a gene that regulates neocorticogenesis. Meta
Gene. 9:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zeng S, Tao Y, Huang J, Zhang S, Shen L,
Yang H, Pei H, Zhong M, Zhang G, Liu T, et al: WD40
repeat-containing 62 overexpression as a novel indicator of poor
prognosis for human gastric cancer. Eur J Cancer. 49:3752–3762.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang Y, Tian Y, Yu JJ, He J, Luo J, Zhang
S, Tang CE and Tao YM: Overexpression of WDR62 is associated with
centrosome amplification in human ovarian cancer. J Ovarian Res.
6:552013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fukasawa K: Oncogenes and tumour
suppressors take on centrosomes. Nat Rev Cancer. 7:911–924. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Godinho SA, Kwon M and Pellman D:
Centrosomes and cancer: How cancer cells divide with too many
centrosomes. Cancer Metastasis Rev. 28:85–98. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Anderhub SJ, Krämer A and Maier B:
Centrosome amplification in tumorigenesis. Cancer Lett. 322:8–17.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chan JY: A clinical overview of centrosome
amplification in human cancers. Int J Biol Sci. 7:1122–1144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Raff JW and Basto R: Centrosome
Amplification and Cancer: A Question of Sufficiency. Dev Cell.
40:217–218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Godinho SA, Picone R, Burute M, Dagher R,
Su Y, Leung CT, Polyak K, Brugge JS, Théry M and Pellman D:
Oncogene-like induction of cellular invasion from centrosome
amplification. Nature. 510:167–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
